Why did 2160.HK stock spike on 27 Feb 2026?

The spike followed analyst price-target upgrades averaging **HK$7.90**, fresh institutional activity and bullish headlines on product adoption. High intraday volume and short‑term momentum amplified the move on the HKSE.

What is Meyka AI’s view on 2160.HK stock valuation?

Meyka AI rates 2160.HK **68.22** (Grade B, HOLD). Our 12‑month forecast is **HK$1.16**, implying downside versus the current **HK$3.89**. The grade balances sector peers, growth and analyst views.

How should traders approach 2160.HK stock after the high-volume session?

Traders should note overbought technicals (RSI **89.10**) and expect volatility. Use tight risk controls, watch volume for confirmation and monitor institutional filings and product adoption updates.

Are analyst price targets aligned with 2160.HK stock forecasts?

No. Analysts’ average target **HK$7.90** implies **+103.34%** upside from **HK$3.89**, while Meyka AI’s 12‑month model estimates **HK$1.16**. This shows a wide divergence between market momentum and model valuations.

HK Stocks

2160.HK MicroPort CardioFlow HKSE closes HK$3.89 27 Feb 2026: high-volume mover

ByDanny Kontos February 27, 2026February 27, 2026

The 2160.HK stock rallied to HK$3.89 at market close on 27 Feb 2026, a 363.10% one-day move on heavy trading that put MicroPort CardioFlow Medtech (HKSE) in the high-volume movers list. The jump followed a sharp analyst price-target lift and notable institutional position changes. Today’s intraday range was HK$3.75–HK$4.20, with volume 1,679,000.00 and visible technical overbought signals. We summarise the drivers, valuation, technicals and what the latest analyst targets mean for Hong Kong-listed MicroPort CardioFlow in HKD